Medicon Hellas S.A. Logo

Medicon Hellas S.A.

Develops, makes, and sells IVD products, analytical systems & software for healthcare providers.

MEDIC | AT

Overview

Corporate Details

ISIN(s):
GRS424003002
LEI:
21380029I4NIQ9ZXE146
Country:
Greece
Address:
MELITONA 5-7, 15344 GERAKAS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Medicon Hellas S.A. is a leading company in the in-vitro diagnostics (IVD) sector. Its operations encompass the research, development, manufacturing, and sale of proprietary IVD products, including diagnostic reagent kits and bulk materials. The company also imports and distributes automated analytical systems from international manufacturers and develops specialized software for laboratory and medical applications. It serves a broad range of healthcare providers, such as public and private hospitals, clinical labs, and diagnostic centers. Products are exported globally through a network of distributors as both branded items and materials for further processing. The company's activities also include providing diagnostic services and manufacturing a line of cosmetics and personal care products. Medicon Hellas operates under key quality certifications, including ISO 13485, and a manufacturer’s license from the National Medicines Organization.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-29 19:30
Interim Report
Οικονομική έκθεση MEDICON ΕΛΛΑΣ A.E (2025,Εξαμηνιαία,Ενοποιημένη)
Greek (modern) 1.8 MB
2025-06-26 09:11
Notice of Dividend Amount
ΟΡΘΗ ΕΠΑΝΑΛΗΨΗ-ΓΝΩΣΤΟΠΟΙΗΣΗ ΑΠΟΚΟΠΗΣ ΔΙΚΑΙΩΜΑΤΟΣ ΜΕΡΙΣΜΑΤΟΣ / ΠΛΗΡΩΜΗΣ ΜΕΡΙΣΜΑΤ…
Greek (modern) 800.1 KB
2025-06-26 09:10
Declaration of Voting Results & Voting Rights Announcements
ΟΡΘΗ ΕΠΑΝΑΛΗΨΗ-ΑΝΑΚΟΙΝΩΣΗ ΓΙΑ ΤΙΣ ΑΠΟΦΑΣΕΙΣ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
Greek (modern) 518.3 KB
2025-06-25 16:42
Declaration of Voting Results & Voting Rights Announcements
ΑΝΑΚΟΙΝΩΣΗ ΓΙΑ ΤΙΣ ΑΠΟΦΑΣΕΙΣ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
Greek (modern) 518.2 KB
2025-05-30 11:14
Pre-Annual General Meeting Information
INVITATION FOR THE ANNUAL GENERAL MEETING 2025
English 490.8 KB

Automate Your Workflow. Get a real-time feed of all Medicon Hellas S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Medicon Hellas S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.